#1 Clinical Trials Search in Europe

Ambrosia Artemisiifolia (302)

This article discusses clinical trials investigating the use of Ambrosia Artemisiifolia (302), commonly known as ragweed, in allergy treatment. These studies aim to assess the effectiveness and safety of sublingual immunotherapy for patients with moderate to severe allergies to various pollens, including birch and grass. The trials focus on determining optimal dosing and evaluating symptom improvement in allergic rhinitis and rhinoconjunctivitis.

Table of Contents

What is AMBROSIA ARTEMISIIFOLIA (302)?

AMBROSIA ARTEMISIIFOLIA (302), also known as ragweed, is a substance derived from the ragweed plant. It is classified as a structurally diverse substance – allergen, which means it is a complex substance that can cause allergic reactions in some people[1]. This substance is used in medical products, particularly for diagnostic purposes in allergy testing.

Medical Uses

The primary medical use of AMBROSIA ARTEMISIIFOLIA (302) is in allergy testing, specifically in the form of a skin prick test. This test is used to diagnose allergies to ragweed pollen[1]. The product containing this substance is classified under the ATC code V04CL, which stands for “Tests for Allergic Diseases”[1].

Ragweed allergy is a common condition that causes symptoms such as:

  • Sneezing
  • Runny or stuffy nose
  • Itchy or watery eyes
  • Itchy throat or ears

By using AMBROSIA ARTEMISIIFOLIA (302) in allergy testing, healthcare providers can accurately diagnose ragweed allergies and develop appropriate treatment plans for patients.

Administration

The product containing AMBROSIA ARTEMISIIFOLIA (302) is administered as a solution for skin-prick test. This means it is applied directly to the skin in a controlled manner during an allergy test[1]. The typical dosage is 1 drop, applied topically (on the skin)[1].

During a skin prick test, a small amount of the allergen solution is placed on the skin, usually on the forearm or back. The skin is then gently pricked to allow the solution to enter the outer layer of skin. If a person is allergic to ragweed, a small, itchy bump (called a wheal) will appear at the test site within about 15-20 minutes.

Clinical Trials

While the provided clinical trial information doesn’t directly study AMBROSIA ARTEMISIIFOLIA (302), it mentions its use as an auxiliary product in trials related to other allergens[1][2]. This suggests that ragweed allergen solutions are being used as part of the diagnostic process in these studies, likely to ensure proper patient selection or to compare allergic responses.

Potential Benefits

The main benefit of using AMBROSIA ARTEMISIIFOLIA (302) in allergy testing is accurate diagnosis. By identifying a ragweed allergy, patients can:

  • Receive appropriate treatment, such as antihistamines or immunotherapy
  • Take steps to avoid or minimize exposure to ragweed pollen
  • Better understand and manage their allergy symptoms
  • Potentially improve their quality of life during ragweed pollen season

Precautions and Considerations

While skin prick tests using AMBROSIA ARTEMISIIFOLIA (302) are generally safe, there are some important considerations:

  • The test should be performed by a trained healthcare professional
  • Patients with severe allergies may be at risk of a stronger reaction
  • Some medications, particularly antihistamines, may interfere with test results and may need to be temporarily discontinued before the test
  • Pregnant women should consult their doctor before undergoing allergy testing
  • People with certain skin conditions may not be suitable candidates for skin prick testing

It’s important to discuss any concerns or questions about allergy testing with a healthcare provider. They can provide personalized advice based on individual health conditions and medical history.

Aspect Details
Study Type Phase II-III clinical trials
Treatment Sublingual immunotherapy
Allergens Studied Birch pollen, Grass pollen, Ragweed (Ambrosia Artemisiifolia)
Primary Objective Establish most effective and best-tolerated dose
Main Outcome Measure Combined Symptom and Medication Score (CSMS)
Participant Age Range 18-65 years
Key Inclusion Criteria Moderate to severe allergic rhinitis/rhinoconjunctivitis, confirmed pollen sensitization
Key Exclusion Criteria Previous immunotherapy, severe asthma, immune system disorders

FAQ

  • What is Ambrosia Artemisiifolia (302)? Ambrosia Artemisiifolia (302) is the scientific name for ragweed, a common allergen used in these clinical trials. It's being studied as part of allergy tests and treatments.
  • What type of allergies are being studied in these trials? The trials are studying moderate to severe allergic rhinitis and rhinoconjunctivitis caused by various pollens, including birch and grass pollen.
  • What is sublingual immunotherapy? Sublingual immunotherapy is a treatment method where small amounts of an allergen are placed under the tongue to help the body build tolerance over time, potentially reducing allergic reactions.
  • Who can participate in these clinical trials? Generally, participants must be between 18 and 65 years old, have a confirmed allergy to the specific pollen being studied, and meet other health criteria. However, there are numerous exclusion criteria that may prevent participation.
  • How is the effectiveness of the treatment measured? The main measure of effectiveness is the Combined Symptom and Medication Score (CSMS) during peak pollen periods. Other measures include quality of life questionnaires, symptom-free days, and nasal provocation tests.

Ongoing Clinical Trials on Ambrosia Artemisiifolia (302)

  • Study on the Effectiveness and Safety of Phleum Pratense Pollen Extract for Patients with Moderate-to-Severe Grass Pollen Allergy

    Not recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Effectiveness and Safety of Sublingual Immunotherapy with Betula Pendula Pollen Extract for Patients with Birch Pollen Allergy

    Not recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Allergic rhinitis: An allergic reaction affecting the nose, causing symptoms such as sneezing, itching, and runny nose.
  • Rhinoconjunctivitis: An allergic condition affecting both the nose and eyes, causing symptoms in both areas.
  • Sublingual immunotherapy: A treatment for allergies where small amounts of an allergen are placed under the tongue to help build tolerance.
  • Combined Symptom and Medication Score (CSMS): A measure used to assess the severity of allergy symptoms and the amount of medication needed to control them.
  • Nasal provocation test: A test where an allergen is applied to the nose to assess the allergic response and sensitivity.
  • FEV1: Forced Expiratory Volume in one second, a measure of lung function used to assess respiratory health.
  • Skin prick test: A method of testing for allergies by applying a small amount of an allergen to the skin and observing the reaction.
  • IgE: Immunoglobulin E, an antibody produced by the immune system in response to allergens.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-sublingual-immunotherapy-with-betula-pendula-pollen-extract-for-patients-with-birch-pollen-allergy/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-phleum-pratense-pollen-extract-for-patients-with-moderate-to-severe-grass-pollen-allergy/